Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Purdue Biologist Stanton B. Gelvin explained how Agrobacterium moves DNA into wounded plant cells, and why cracking that “black box” matters for agriculture during a seminar Wednesday afternoon at the ...

February 25, 2026 marks one year since KJ, an infant born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, became the world's first person to receive a personalized CRISPR-based gene ...

After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...

The cardiology landscape is rapidly evolving. Novel risk factors and new tools are reshaping CV risk assessment and ...

"Gene editing takes centre stage in FDA’s new rare disease approval pathway" was originally created and published by ...

The Food and Drug Administration on Monday laid out a new pathway aimed at spurring novel individualized treatments targeting ...

Mars is leaning harder into M&M’s as a strategic growth engine while navigating major acquisitions, volatile cocoa markets, ...

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.